Business
Virax Biolabs Enrolls First Patients in Clinical Study Assessing T cell Dysfunction in Post-acute Infection Syndromes
Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, announced today that it has started enrolling patients into its United Kingdom based, multi-center clinical study (NCT06731179).
About this update from Virax Biolabs Group Limited
[{"type":"text","content":"LONDON, March 18, 2025 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, announced today that it has started enrolling patients into its United Kingdom based, multi-center clinical study (NCT06731179).","length":372,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Virax Biolabs)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Virax Biolabs)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":60,"url":"https://media.zenfs.com/en/prnewswire.com/44cb7bd927e7b684aa08d6c73aae1120"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/DWG.2rb5wHiwumRjnTwc7A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTEwNjtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/44cb7bd927e7b684aa08d6c73aae1120","width":400,"height":60}},"href":"https://mma.prnewswire.com/media/1879039/Virax_Biolabs_Logo_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Conducted in collaboration with the United Kingdom's National Health Service, investigators aim to assess the ViraxImmune™ FluoroSpot T cell assay performance in detecting T cell dysfunction in post-acute infection syndrome patients, including those with long COVID, post-treatment Lyme disease (PTLD), and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). As part of the regulatory approval pathway, up to 200 participants will be enrolled into the study, with initial data from this longitudinal assessment expected in Q2 2026.","length":544,"tagName":"p"},{"type":"text","content":""There are currently no reliable diagnostics for patients with these conditions associated with post-acute infection syndromes," said James Foster, CEO of Virax Biolabs, "The data generated from this clinical study will provide additional insights into the immune dysregulation in these conditions, enabling us to improve diagnostics and patient care. ViraxImmune™ has the potential to improve the assessment of immune health, ultimately paving the way for earlier treatment intervention and better patient outcomes."","length":537,"tagName":"p"},{"type":"text","content":"About Virax Biolabs Group Limited","length":33,"tagName":"p"},{"type":"text","content":"Virax Biolabs Group Li...